Strong growth masks gross margin compression; long-term roadmap intact but near-term headwinds

Delivered 19.2% YoY; but QoQ down 7.7%, showing sequential softness despite annual guidance

Q1 FY27 EBITDA margin 24.58%; down from ~26% levels, contradicting 25% consistency claim

Gross margin fell 650 bps (51%→44.2%); RMC now ~48% vs historical 44%. Analyst challenged this as material

6,000 MT expansion delayed from June to September 2026 (3-month slip acknowledged)

Reaffirmed in call; but compressed margins and delayed capex raise execution risk on timeline

Management claimed '25% margins consistently over 9 quarters' but Q1 is 24.6% with gross margin at 44.2% (vs 51% Q1 FY26). Structural cost inflation in RMC not yet resolved.

Phase-1 expansion (6K MT) originally June 2026, now September 2026 (3-month slip). Management says 'on track overall' but acknowledge rain/weather delays.

Running at ~90% utilization; steady state. No new data vs prior call but healthy backlog implied by sustained demand.

Board directive now restricts disclosure of segment/product mix. Analyst Vivek pressed hard; CFO deflected. Opacity flag.

Chairman pivoted from PRIGIV-style JVs to 'strategic alliances' for future partnerships (avoiding customer favoritism optics). Two alliances underway, not named.

RMC percentage consumption at ~48% this quarter (vs 52-55% normalized range). CFO cited high raw material import cycle and product mix; Sanjeev said 75 products use 60 different RMs. Claimed economies of scale will offset. No specific recovery timeline.

Phase-1 (6K MT) now Sept 2026 (delayed from June). Phase-2 (12K MT) by Sept 2027. Sanjeev: 'No change in guidance. We will achieve 5K, 1K in promised time.' Acknowledged minor delays from rain but project on track overall.

Putting up 2-ton/day demo plant in Navi Mumbai (vs few hundred kg fortnightly now). Investment post-5K plan (12-15 months lead, 1-year learning, then large-scale). Chairman: Bio-tech not in 5K roadmap; comes after 5K achieved.

PRIGIV revenue ~₹18 Cr with EBITDA margin 14-15%. Achieved profitability in Q4 FY26, now scaling. Investing additional ₹50 Cr equity.

Sanjeev: Cannot predict commodity prices. CST procurement via back-to-back customer contracts hedges cost. Balance alpha-pinene from GTO at historic highs; pass-through to customers possible.

Camphor is 5-6% of revenue, non-strategic. Different sourcing (GTO vs CST) means competitors' volatility doesn't directly impact Privi. 'We sell on our terms.'

Filed with NCLT in Q1 post stock exchange observation letters. Expected to close by end of FY27. Adds ~6K MT post-merger capacity.

Pine is main contributor. Narayan: Board directive restricts product segment disclosure. All products 90% capacity utilized; diversified portfolio is the answer.

Maltol/Ethyl Maltol >95% made in China. Ethyl Maltol for pharma (import substitute). Maltol for flavor (Ovaltine, chocolate, biscuits). Privi capacity ~1/4 of global opportunity. Only company fully backward-integrated (cob→Maltol). Confidence in scale-up via cost advantage.

Furfural as building block from corn cob (fully integrated). Maltol, Ethyl Maltol, Cyclopentanone, Musk T, ~10 more specialty molecules. Plants under implementation, mechanical completion by mid-FY28, H2 FY28 contribution expected.

Existing molecules: 2-4 reactions per molecule; continuous on 2-3 in some cases. Most distillations now continuous. New molecules like Maltol targeting continuous start. Specialty products cannot be continuous but optimizing existing lines.

Red Sea impact ongoing for years; navigating through. Hormuz Strait freight not materially impacted margins. No specific threat seen to costs.

Narayan: Cannot disclose details at this time. Sanjeev: Typically for 1-2 specific molecules customers want exclusively. Will announce at appropriate time.

Management reaffirmed 5K, 1K target in 3-4 years (to FY30). Chairman: 20% CAGR with similar EBITDA margins. Mechanism: Phase-1/2/3 capex (48K→70K+ MT), Maltol/furfural/specialty molecules.

Q1 EBITDA 24.6%, below 25% target. CFO claims operational efficiencies and product mix will drive recovery. RMC normalization assumed but timeline unclear. Gross margin compression (650 bps) is near-term drag.

Split: ₹300Cr existing product (Phase-1 delayed to Sep 2026); ₹300Cr new products (Maltol, mid-FY28 close); ₹300Cr specialty (H2 FY28 contribution). Funded primarily via internal accruals + selective borrowing at competitive rates.

RMC at ~48% of sales (vs 44-45% structural baseline); 650 bps gross margin compression YoY. CFO cites cyclical nature and 52-55% normalized range but offers no recovery timeline.

Phase-1 (6K MT) delayed from June 2026 to September 2026 (3-month slip). Phase-2 timing (Sep 2027) and subsequent phases dependent on execution. Risk compounds FY30 5K target.

Management stopped disclosing product mix and segments per Board directive. Pine products main revenue driver but size/growth unmeasured. 75 products on 60 raw materials creates skew risk.

Maltol/Ethyl Maltol, Musk T, and 10+ specialty molecules in Phase-2/3 pipelines. Ethyl Maltol (pharma) requires regulatory approvals; Maltol (flavor) requires GMP certification. Timeline to commercial scale not specified.

Red Sea, Hormuz Strait, Iran war cited. Freight cost inflation risk; crude-based raw materials (15-18% of purchases) exposed to geopolitical spillover.